State Street's passive 7.6% stake adds to the existing passive positions from Vanguard (8.6%) and Madison Avenue Partners (6.4%), bringing total disclosed passive ownership to ~22.6%. Monitor for any future 13D conversion or additional insider buying/selling ahead of upcoming catalysts.
RARE drugs
RARE drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $16.14entry
- T+1 · 6d ago +3.47%α +2.15% · $16.70
- T+4 · todayOpen
- T+5 · in 3h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corporation filed a Schedule 13G disclosing a 7.6% passive stake in Ultragenyx Pharmaceutical as of September 30, 2026, held primarily through its SSGA Funds Management subsidiary (5.4%). This is a routine passive filing by a large custodian bank and asset manager, indicating no intent to influence control.
Key Financial Metrics
Key Facts
- State Street Corp disclosed beneficial ownership of 7,538,078 shares of Ultragenyx common stock, representing 7.6% of shares outstanding as of September 30, 2026.
- SSGA Funds Management, Inc., a State Street subsidiary, holds 5,318,630 shares (5.4%) as an investment adviser.
- The filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control.
- This is an initial SC 13G filing by State Street for Ultragenyx; no prior 13G/D from this filer appears in the cross-filing context.
Financial Impact
State Street's stake is valued at approximately $122M based on the $1.6B market cap snapshot, representing 7.6% ownership.
Risk Factors
- No activist intent is signaled; this is a routine passive filing by a large custodian bank.
- The filing does not provide any new information about Ultragenyx's business or financial outlook.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000734 |
| Document: 0000093751-26-000734-index.html | 0000093751-26-000734 |
| Document: 0000093751-26-000734.txt | 0000093751-26-000734 |
Track record
22 reports on RARE
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers